

FORM 7
MONTHLY PROGRESS REPORT
For the Month of August 2020

Name of CSE Issuer: **MYM Nutraceuticals Inc. (the “*Issuer*”).**

Trading Symbol: **MYM**

Number of Outstanding Listed Securities: **226,761,095 common shares**

Date of filing: **September 11, 2020**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Highland Grow Inc.

During the month of August, the Issuer has taken over the management of its newest acquisition: Highland Grow Inc. The management team has been redefined with Michael Wiener joining the Issuer as a Director and CEO and Robert Wolf being appointed to the board of directors as an independent director. The Issuer intends to sell into new provinces in the near term.

SublimeCulture Inc.

The Company has commenced cultivation, and expects its first batch of dried flower to be available for sale in the month of October.

2. Provide a general overview and discussion of the activities of management.
See #1 above.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

With the acquisition of Highland Grow Inc., the Company has added several products to its portfolio including flower and pre-rolls. A detailed description of the Company’s products can be viewed at <https://www.highlandgrow.com/products/>.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

As part of the Highland Grow acquisition, the Issuer has acquired supply and purchase contracts with several provincial authorities, licensed cannabis retailers, and/or licenced producers, respectively.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

On August 4, 2020, the Company announced that it closed the transactions previously announced in its press release dated July 27, 2020, pursuant to which MYM acquired 100% of Biome Grow Inc.'s wholly-owned subsidiary Highland Grow Inc., which is licensed under the *Cannabis Act (Canada)* to cultivate, process, and distribute cannabis from its facility located in Antigonish, Nova Scotia.

8. Describe the acquisition of new customers or loss of customers.

See #5 above.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

As part of the acquisition of Highland Grow Inc., the Issuer has acquired a Standard Cultivation, Processing and Sales Licence issued in accordance with the Cannabis Act and Cannabis Regulations.

In addition, the Issuer has acquired several intangible assets including brand names (i.e. Highland Grow and Coastal Connections) and customer lists.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

As part of the acquisition of Highland Grow Inc, the Issuer has acquired all of the employees of Highland Grow Inc. In addition, several key employees of Biome Grow Inc., have transferred to the Issuer.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

During the month of August, the Issuer, through one of its subsidiaries (Highland Grow Inc.) became party to a Notice of Action for Debt in the amount of \$28,750.00 filed in the Supreme Court of Nova Scotia on August 26, 2020. Management is reviewing the claim and plans to respond accordingly.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

To finance the acquisition of Highland Grow Inc., and to provide additional working capital, the Issuer has entered into a loan facility (the "Loan Facility") with 1909203 Ontario Inc. (the "Facility Lender") whereby the Issuer borrowed \$3 million for a term of 18 months with an option to extend for an additional 6 months at the sole discretion of the Issuer upon the Issuer paying the Facility Lender an extension fee. 1909203 Ontario Inc., is controlled by Michael Wiener and parties related to him. The Loan Facility shall bear interest at a face rate of 17.5% per annum. The Issuer shall also pay the Facility Lender a set-up fee equal to 3% of the amount advanced and an immediate interest payment equal to 5% of the amount advanced separate from and in addition to the 17.5% per annum interest payable under the Loan Facility. The Loan Facility is secured against all of the Issuer's current and future acquired assets. At any time during the term of the Loan Facility, at the Issuer's discretion, the Issuer may borrow an additional \$1 million from the Facility Lender on the same terms and conditions as the \$3 million loan upon issuing the Facility Lender warrants to purchase 28,571,429 common shares of the Issuer with an exercise price of \$0.07 per common share. During the month of August 2020, the Issuer initiated a draw of \$600,000.00 against the additional loan amount.

<u>Date of Draw</u>	<u>Amount</u>
July 31, 2020	\$3,000,000
<u>August 25, 2020</u>	<u>\$ 600,000</u>
Total outstanding amount	\$3,600,000
Additional facility available	\$ 400,000

14. Provide details of any securities issued and options or warrants granted.

During the month of August, the Issuer:

- **Granted a total of 23,980,000 stock options to certain directors, officers, employees and consultants of the Issuer. The stock options are exercisable for a period of three years from the date of grant at a price of \$0.065 per Share. Certain stock options will vest immediately, and certain stock options will vest over a period of 12 months in 12 equal proportions.**
- **Announced that it borrowed an additional \$600,000.00 pursuant to the Loan Facility with 1909203 Ontario Inc., (the “Lender”) previously announced on July 27, 2020. As consideration for such loan, the Issuer has issued the Lender 28,571,429 common share purchase warrants each of which may be exercised to purchase one common share of the Issuer at a price of \$0.07 per common share for a period of 36 months.**
- **Issued 668,760 common shares for debt of the Issuer at a deemed price of \$0.06 per Share pursuant to certain employment and consulting agreements that contain provisions for the issuance of Shares as part of the compensation.**

15. Provide details of any loans to or by Related Persons.

As part of the acquisition agreement, the Issuer loaned Biome Grow Inc., (“Biome”) an amount equal to \$1 million (the “Biome Loan”) for a term of 18 months with an option to extend for an additional 6 months at the sole discretion of Biome upon Biome paying an extension fee. The Biome Loan shall bear interest at a face rate of 17.5% per annum. Biome shall also pay a set-up fee equal to 3% of the amount advanced and an immediate interest payment equal to 5% of the amount advanced separate from and in addition to the 17.5% per annum interest payable under the Biome Loan. Interest on the Loan shall be payable monthly beginning on the day that is 4 months following the advance of the Loan. Requiring no further loan of cash by the Issuer, the principal amount of the Biome Loan shall be increased by the amount of certain liabilities of Highland Grow Inc., which will continue to be owing by Highland Grow Inc., postclosing estimated to be approximately \$1.4M.

16. Provide details of any changes in directors, officers or committee members.

Mark Forster was re-appointed as Chief Financial Officer of the Company. Robert Wolf and Edward Tabisz were appointed to the Audit Committee. Robin Linden and Robert Wolf were appointed to the Compensation Committee.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

On March 11, 2020, the World Health Organization (WHO) declared COVID-19 a global pandemic. It has adversely affected global workforces, economies, and financial markets, triggering an economic downturn and is expected to impact many retail businesses including dispensaries. It is not possible at this time for the Issuer to predict the duration or magnitude of the adverse results of the outbreak nor its effects on the Issuer's business or operations.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: September 11, 2020

Robin Linden
Name of Director or Senior Officer

"Robin Linden"
Signature

Director
Official Capacity

Issuer Details		
Name of Issuer MYM Nutraceuticals Inc.	For Month End August, 2020	Date of Report 20/09/11
Issuer Address 1500 – 409 Granville Street		
City/Province/Postal Code Vancouver, BC V6C 1T2	Issuer Fax No. ()	Issuer Telephone No. 778.522.2261
Contact Name Robin Linden	Contact Position Director	Contact Telephone No. 778.522.2261